In this episode, John Mascarenhas, MD, and Ruben A. Mesa, MD, FACP, discuss current best practices and emerging approaches for treating patients with myelofibrosis, including:

• Overall approach to treatment
• Use of JAK inhibitors for treating myelofibrosis
• Treating patients with low platelets
• Defining JAK inhibitor failure
• Unmet needs in treatment and emerging therapeutic options, including momelotinib, luspatercept, ruxolitinib add-on therapy, and other phase III approaches

Presenters: 

John Mascarenhas, MD
Professor of Medicine

Icahn School of Medicine at Mount Sinai

Director, Adult Leukemia Program

Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute

New York, New York

Ruben A. Mesa, MD, FACP
Executive Director, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Enterprise Senior Vice President, Atrium Health

President, Enterprise Cancer Service Line

Vice Dean for Cancer Programs, Wake Forest University School of Medicine

Professor of Medicine, Wake Forest University School of Medicine 

Winston-Salem, North Carolina